Drug Profile
Carbidopa/levodopa - SynAgile
Alternative Names: Carbidopa/levodopa continuous-release - SynAgile; DopaFuse; L-DOPA/carbidopa continuous-release - SynAgile; Levodopa/carbidopa continuous-release - SynAgileLatest Information Update: 25 Aug 2022
Price :
$50
*
At a glance
- Originator SynAgile Corporation
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Parkinson's disease
Most Recent Events
- 02 Aug 2022 SynAgile Corporation completes a phase-II trial in Parkinson's disease (Adjunctive treatment) in Spain, Luxembourg and Italy (PO) (NCT04778176)
- 16 Jun 2021 Phase-II clinical trials in Parkinson's disease (Adjunctive treatment) in Spain (PO) (NCT04778176)
- 16 Jun 2021 Phase-II clinical trials in Parkinson's disease (Adjunctive treatment) in Italy, Luxembourg (PO) (NCT04778176)